Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …

Simple Summary The breakthrough in developing novel HER2-targeting antibody drug
conjugates and identifying their clinical benefits in HER2-low breast cancer will dramatically …

Background Among breast cancers without human epidermal growth factor receptor 2
(HER2) amplification, overexpression, or both, a large proportion express low levels of …

Importance Given conflicting results regarding the prognosis of erb-b2 receptor tyrosine
kinase 2 (ERBB2; formerly HER2 or HER2/neu)–low breast cancer, a large-scale, nationally …

PURPOSE To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-
drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a …

Background Recently, novel antibody––drug conjugates (ADCs) showed clinical activity in a
subset of advanced human epidermal growth factor receptor 2 (HER2)-negative patients …

Background The interest in HER2-low breast cancer (BC) has increased in recent years with
the development of novel anti-HER2 antibody–drug conjugates. Here, we investigated the …

The identification of the HER2 alteration as an actionable oncogenic driver in breast cancer
has propelled the development of HER-targeting monoclonal antibodies (mAb) such as …

Breast cancer is one of the main cause of cerebral and leptomeningeal metastases, the
prognosis of which remains poor to this day. Most studies excluded patients with active brain …

Simple Summary Antibody–drug conjugates (ADCs) are a growing class of therapies that
aim to delivery therapy more efficiently, with fewer side effects, than conventional …